Back
Biogen Inc. (BIIB)
BiotechnologyBIIB · NASDAQ NMS - GLOBAL MARKET · USD
New to investing? How to read this page →$198.70
−0.81%Price · 1 year
Loading live analysis…
Loading analysis…
Intrinsic Investor is for education and research only — not financial advice.
Key metrics
EPS
$8.79
ROE
7.7%
Gross margin
78.7%
Debt/Equity
0.35x
Revenue growth
1.9%
Biogen Inc. — company intelligence
Earnings surprises
Q1 2026$3.57 vs $2.83 est+26.3%
Q4 2025$1.99 vs $1.65 est+20.9%
Q3 2025$4.81 vs $3.96 est+21.5%
Q2 2025$5.47 vs $3.94 est+38.9%
Insider activity · 90 days
9 buys1 sellnet +13,590 shares
SHERWIN STEPHEN ABuy 1,505 · Jun 9, 2026
HAWKINS WILLIAM ABuy 1,505 · Jun 9, 2026
Rowinsky Eric KBuy 1,505 · Jun 9, 2026
Recent SEC filings
8-K — Material event reportJul 1, 2026
4 — Insider transaction reportJun 11, 2026
4 — Insider transaction reportJun 11, 2026
Latest news
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now — Yahoo · 5d ago
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors. — Yahoo · 1w ago
BIIB Stock Ends 3% Higher — Why This Strategist Picks Biogen Over Other Biotech Peers — Yahoo · 1w ago
Is Biogen (BIIB) Priced Near Fair Value After Its 57% Run? — Yahoo · 1w ago
Biogen (BIIB) To Share New Alzheimer’s Data At AAIC 2026 — Yahoo · 1w ago
AI Valuation Narrative
Generates a short bull / bear / catalyst summary from the analytics we already computed. No target prices. Research tool, not investment advice.
Explore more
Peers & similar stocks
Quick links to related tickers for research.
About Biogen Inc.
Weekly undervalued picks (like BIIB)
Get 3 new value ideas and the fair-value math behind them every week. One email, unsubscribe anytime.
Free. No spam. We only email once per week.
Data is provided "as-is" and may be delayed or incomplete. Intrinsic Investor is for education only and is not investment advice.